RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Solid Tumor|Triple Negative Breast Cancer
Interventions: DRUG: RX-5902
Sponsor: Rexahn Pharmaceuticals, Inc.